Diagnosis and management of ankylosing spondylitis

British Medical Journal

Volumn 333, Issue 7568, 2006, Pages 581-585

  McVeigh, Claire M ^a   Cairns, Andrew P ^a  

^a MUSGRAVE PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PAMIDRONIC ACID; PARACETAMOL; SALAZOSULFAPYRIDINE;

ANKYLOSING SPONDYLITIS; CARDIOVASCULAR RISK; CLINICAL EXAMINATION; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DRUG MECHANISM; FRACTURE; GENETIC PREDISPOSITION; HUMAN; IMAGING SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PHYSIOTHERAPY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SURGICAL TECHNIQUE;

HUMANS; MEDICAL HISTORY TAKING; PHYSICAL EXAMINATION; REFERRAL AND CONSULTATION; SPONDYLITIS, ANKYLOSING;

EID: 33748921689     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.38954.689583.DE     Document Type: Review

References (29)

1. Gran JT, Husby G. Epidemiology of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology. 3rd ed. London: Mosby, 2003:1153-9.
2. Moll JM, Wright V. New York clinical criteria for ankylosing spondylitis: a statistical evaluation. Ann Rheum Dis 1973;32:354-63.
3. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
4. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005;52:1000-8.
5. Khan MA. Clinical features of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology. 3rd ed. London: Mosby, 2003:1161-81.
6. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006;54:569-78.
7. Yu W, Feng F, Dion E, Yang H, Jiang M, Genant HK. Comparison of radiography, computed tomography and magnetic resonance imaging in the detection of sacroileitis accompanying ankylosing spondylitis. Skeletal Radiol 1998;27:311-20.
8. Braun J, Landewe R, Hermann KG, Han J, Yan S, Williamson P, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicentre, randomised, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-52.
9. Baraliakos X, Brandt J, Listing J, Haibel H, Sorensen H, Rudwaleit M, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 2005;53:856-63.
10. Balint PV, Kane D, Wilson H, McInnes EB, Sturrock RD. Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy. Ann Rheum Dis 2002;61:905-10.
11. Cairns AP, Wright SA, Taggart AJ, Coward SM, Wright GD. An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover. Ann Rheum Dis 2005;64:338-9.
12. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis J, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;54:442-52.
13. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-32.
14. Dagfinrud H, Kvein TK, Hagen K. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2004;(4):CD002822.
15. Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis. Arthritis Rheum 2005;52:1756-65.
16. Chen J, Liu C. Sulphasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005;(2):CD004800.
17. Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClerq S, Chiu P, Yan A, et al. A six-month randomised, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal anti-inflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46:766-73.
18. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumour necrosis factor alpha. N Engl J Med 2002;346:1349-56.
19. Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumour necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomised, controlled trial. Arthritis Rheum 2003;48:3230-6.
20. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600.
21. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-97.
22. Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomised controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
23. Van der Heijde D, Kivitz A, Schiff M, Sieper J, Dijkmans B, Braun J, et al. Adalimumab therapy significantly reduces signs and symptoms in patients with ankylosing spondylitis (AS): results of the ATLAS trial. [abstract] Rheumatology (Oxford) 2006;45(suppl 1):OP15.
24. Sieper J, Baraliakos X, Listing J , Brandt J, Haibel H, Rudwaleit M, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 years of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) 2005;44:1525-30.
25. Keat A, Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, Paul S, et al. BSR guidelines for prescribing TNF-α blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology (Oxford) 2005;44:939-47.
26. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol 1994;21:2286-91.
27. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70.
28. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
29. Cairns AP, Taggart AJ. Tumour necrosis factor inhibitors: maximizing patient safety. Rheumatology (Oxford) 2003;42:188-9.